buserelin

(redirected from Suprefact)

buserelin

A long-acting GnRH-gonadotropin-releasing hormone analogue, which causes permanent pitutary stimulation and downregulates the pituitary-gonadal axis, blocking testosterone production in the testes; it has been used to treat metastatic prostate and breast cancer, to create pseudomenopause to reduce the size and number of endometriotic lesions and fibroids. It has also been used for hirsutism, to induced ovulation and for in vitro fertilisation.

buserelin

Suprefact® Infertility A long-acting gonadotropin-releasing hormone analogue which downregulates the pituitary-gonadal axis, block testosterone production in the testes; it has been used to treat metastatic prostate CA. See Disease flare.

buserelin

A gonadothropin-releasing hormone drug used in the treatment of ENDOMETRIOSIS and INFERTILITY. Brand names are Suprecur and Suprefact.
Mentioned in ?
References in periodicals archive ?
Long protocol of down regulation of ovaries was achieved by sub cutaneous administration of 1 mg of subcutaneous Buserelin Acetate (Suprefact, Sanofi Aventis, Pakistan) in mid luteal phase of previous cycle.
After the patients were assessed for eligibility according to the mentioned criteria, a standard downregulation protocol was performed for all of them via a subcutaneous injection of GnRH agonists (0.5 mg of buserelin, Suprefact, Serono), on day 21 of their menstrual cycle (1 wk before the expected menses).
All patients underwent conventional IVF/ICSI treatment with the standard long protocol using a GnRH agonist (Suprefact, Hoechst, Frankfurt, Germany) for pituitary suppression.
After the initial work-up, controlled ovarian hyperstimulation (COH) was done with the long protocol: Gonadotropin-releasing hormone agonist (GnRH agonist; injection Suprefact 0.5cc) was started in the luteal phase (Day 21) of the preceding cycle; 150 IU of human menopausal gonadotropin (hMG) was started at day 3 of the cycle; and 10,000 international units (IU) of human chorionic gonadotropin (hCG) was given to trigger ovulation.
In addition, the brand of LHRH agonist (Lupron [Abbott Laboratories, Saint Laurent,QC], Zoladex [AstraZeneca Canada, Mississauga, ON], Suprefact [sanofi-aventis, Laval, QC], Eligard [sanofi-aventis, Laval, QC], Trelstar [Watson Pharma Inc., Parsippany, NJ] was recorded.
However this tremendous discrepancy in price does not simply include basic pain relief, but also antibiotics such as Dalacin and Augmentin, cancer medication such as Casodex and Suprefact, along with anti-depression medication such as Xanax and Lexotanil, among others.
Follicles were aspirated under ultrasound-guided transvaginal puncture after pituitary desensitization with Buserilin nasal spray (800 [micro]g daily; Suprefact, Hoechtst, Belgium) followed by human menopausal gonadotropin (hMG), only 2 ampules of 75 U daily until at least two follicles reached a diameter of 20 mm.
The downregulation protocol was used for all the patients via a subcutaneous injection of GnRH agonists (0.2 mg buserelin, Suprefact, Serono, Rome, Italy), starting from the 21st day of the same cycle when melatonin was started.
1 mg of subcutaneous Buserelin Acetate (Suprefact) was initiated on day 21 to achieve adequate ovarian suppression, followed by recombinant FSH (Gonal-f) or hMG (Menogon).
Down regulation and ovulation induction was performed by the administration of gonadotrophin-releasing hormone (GnRH) agonist (Suprefact or Decapeptyl) together with gonadotrophins.